Molecular Partners Ag (MOLN) Asset Utilization Ratio (2021 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Asset Utilization Ratio of 0.07 for Q1 2026, up 8.06% year-on-year from 0.06 in Q1 2025, and down 58.86% on a QoQ basis from 0.04 in Q4 2025.
Molecular Partners Ag (MOLN) Asset Utilization Ratio (2021 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Asset Utilization Ratio for 6 consecutive years, with 0.07 the latest figure, recorded in Q1 2026.
- Quarterly Asset Utilization Ratio rose 8.06% year-over-year to 0.07 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.07 (up 8.06% YoY) and the FY2025 annual result came in at 0.0, down 100.0% from the prior year.
- Asset Utilization Ratio slipped to 0.07 in Q1 2026 per MOLN's latest filing, from 0.04 in the prior quarter.
- Over the last five years, Asset Utilization Ratio for MOLN reached as high as 0.04 in Q1 2023 and fell as low as 80763.91 in Q3 2025.
- A 5-year average of 4750.82 and a median of 0.02 in 2022 frame the typical range for Asset Utilization Ratio.
- Annual changes were most pronounced in 2023 — Asset Utilization Ratio jumped 32713.05% — and 2025, when it tumbled 228798333.76%.
- Year by year, Asset Utilization Ratio stood at 0.02 in 2022, then soared by 49.01% to 0.03 in 2023, then sank by 206.2% to 0.03 in 2024, then plunged by 46.97% to 0.04 in 2025, then plunged by 58.86% to 0.07 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.07, 0.04, and 80763.91 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 0.69 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.47 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.37 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | -0.07 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.07 |
| Dec 31, 2025 | -0.04 |
| Sep 30, 2025 | -80,763.91 |
| Jun 30, 2025 | -0.07 |
| Mar 31, 2025 | -0.07 |
| Dec 31, 2024 | -0.03 |
| Sep 30, 2024 | 0.04 |
| Jun 30, 2024 | 0.03 |
| Mar 31, 2024 | 0.03 |
| Dec 31, 2023 | 0.03 |
| Sep 30, 2023 | 0.03 |
| Jun 30, 2023 | 0.04 |
| Mar 31, 2023 | 0.04 |
| Dec 31, 2022 | 0.02 |
| Sep 30, 2022 | 0.02 |
| Jun 30, 2022 | 0.00 |
| Mar 31, 2022 | -0.01 |
| Dec 31, 2021 | 0.00 |